Ardelyx (ARDX) Stock Price
Ardelyx Price
Over the last 13 years Ardelyx grew revenue by 39.4% annually, reaching 407.32 M USD. For Ardelyx, the net margin of -15.1% is up versus -1,566.5% a few years ago. The consensus 12-month price target for Ardelyx is 12.75 USD, about 281.7% above where the stock trades today. Of 17 analysts, 15 rate the stock a buy — an overall Buy consensus.
Ardelyx stock price
Ardelyx business model & stock analysis
Frequently asked questions about Ardelyx
The business model of Ardelyx Inc revolves around developing and commercializing innovative therapeutics for patients with cardio-renal and gastrointestinal diseases. Ardelyx focuses on discovering and developing small molecule therapeutics that address unmet medical needs. The company's approach involves designing drugs that selectively modulate key molecules involved in specific disease processes. By targeting these molecules, Ardelyx aims to develop treatments that improve patients' quality of life and clinical outcomes. Ardelyx Inc strategically collaborates with partners to advance its pipeline and bring novel therapies to market, aiming to make a positive impact on patients' lives.
Ardelyx Inc is primarily active in the pharmaceutical industry.
The main competitors of Ardelyx Inc in the market include pharmaceutical companies such as Ardelyx Pharmaceuticals Inc, AstraZeneca plc, Bayer AG, Johnson & Johnson, Pfizer Inc, and GlaxoSmithKline plc. These companies also operate in the pharmaceutical industry and may offer similar products or target a similar customer base.
Ardelyx Inc is a renowned biopharmaceutical company specializing in the development and commercialization of innovative therapeutic solutions for cardio-renal diseases. Established in 2007, Ardelyx has consistently worked towards addressing unmet medical needs through its proprietary drug discovery platform. The company focuses on designing small molecule therapeutics to target biological pathways involved in the treatment of conditions like hyperkalemia, IBS-C, and CKD. Ardelyx has successfully advanced its candidates through clinical trials, demonstrating their potential efficacy and safety. With a strong commitment to improving patient outcomes, Ardelyx continues to make significant strides in the field of biopharmaceuticals.
Ardelyx Inc has achieved several significant milestones in its journey. The company received FDA approval for its first product, a potassium binder called KAYEXALATE(R). This milestone marks a major breakthrough in addressing hyperkalemia, a condition characterized by high levels of potassium in the blood. Furthermore, Ardelyx advanced its research pipeline to develop innovative therapeutics for cardiorenal diseases and gastrointestinal disorders. The company also attained positive Phase 3 results for tenapanor, an investigational treatment for irritable bowel syndrome with constipation and hyperphosphatemia. With these achievements, Ardelyx Inc has positioned itself as a leading player in the healthcare industry.
Ardelyx Inc is primarily present in the United States, focusing on the development and commercialization of innovative medicines.
Ardelyx Inc represents a strong commitment to improving patient lives through innovative solutions. The company's corporate philosophy revolves around scientific excellence, collaboration, and a patient-centric approach. Ardelyx's values emphasize the pursuit of innovation, integrity, and quality in delivering transformative therapies. With a focus on developing novel treatment options for people with kidney and cardiovascular diseases, Ardelyx aims to address significant unmet medical needs. By combining dedicated research efforts, strategic partnerships, and a patient-centered mindset, Ardelyx Inc strives to create a positive impact and provide effective solutions in the healthcare industry.
18 analysts currently rate the Ardelyx stock: 17 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Ardelyx to generate revenue of 488.78 M USD and earnings per share of -0.18 USD.
Converted at the current exchange rate, the Ardelyx share trades at 2.97 EUR (3.34 USD).
The Ardelyx share (ARDX) is listed on 5 stock exchanges, including: NASDAQ (ARDX), SIX (Zürich) (41X.SW), Frankfurt (41X.F), München (41X.MU), Düsseldorf (41X.DU).
Ardelyx Inc. is a biopharmaceutical company based in the United States that focuses on developing medical solutions for the treatment of kidney and gastrointestinal diseases. The company was founded in 2007 and is headquartered in Fremont, California. Ardelyx has three main business areas: kidneys, gastrointestinal tract, and cardiology. Within these areas, the company focuses on developing innovative drugs based on the effects of intestinal hormones. The company's main focus is on the treatment of hyperphosphatemia, a kidney disease characterized by high levels of phosphate in the blood. Ardelyx has developed a drug called Tenapanor, which has shown promising results in clinical studies for reducing phosphate levels in the blood. The company also focuses on treating gastrointestinal diseases such as irritable bowel syndrome and chronic kidney failure. Ardelyx has an extensive portfolio of patents and intellectual property and has numerous partnerships with other pharmaceutical and biotechnology companies to reduce development costs and accelerate research activities. The company has received significant investments from venture capital firms and other financial investors in recent years. Ardelyx went public in 2014 and raised approximately $60 million. The company's business model is based on developing innovative medical solutions based on the research of intestinal hormones, with partnerships being an important component to leverage resources and expertise. Ardelyx aims to expand its research and development activities and expand its product pipeline by collaborating with other companies and leveraging synergies through partnerships. Overall, Ardelyx is a promising company in the field of biopharmaceutical research and development. With a broad portfolio of patents and intellectual property and a focus on researching new drugs and therapy approaches, Ardelyx has the potential to become a key player in drug development in the future.
The expected revenue of Ardelyx is 488.78 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Ardelyx is -44.15 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Ardelyx is currently -18.43. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Ardelyx stock.
The price-to-sales ratio (P/S) of Ardelyx is currently 1.66. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Ardelyx stock.
The Eulerpool Quality Score for Ardelyx is 4/10.
The ISIN of Ardelyx is US0396971071. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Ardelyx is A116X0. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Ardelyx is ARDX. The ticker symbol is used to trade Ardelyx shares on the stock exchange.
Ardelyx stock
Ardelyx Ticker
Ardelyx FIGI
All fundamentals and in-depth analysis of Ardelyx
Our stock analysis for Ardelyx stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ardelyx. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.